- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05380583
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
November 6, 2023 updated by: Julie McCarthy, Ph.D., Mclean Hospital
Treatment Engagement in Families With Substance Use and Psychosis: A Pilot Study
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth (video conferencing).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The intervention aims to improve treatment engagement, substance use patterns, and family wellbeing.
To assess preliminary outcomes of the intervention, this study compares CRAFT-EP plus treatment as usual (TAU) compared to TAU alone.
Family members will be randomized to CRAFT-EP + TAU or TAU alone.
Data on family members and clients with psychosis will be collected for assessment purposes; if a client with psychosis does not have a family member participating in the study, the client with psychosis will be automatically be assigned to the TAU alone group.
Total target enrollment is 40 family members and 40 clients with psychosis.
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Julie M McCarthy, PhD
- Phone Number: 617-855-3521
- Email: jmccarthy@mclean.harvard.edu
Study Contact Backup
- Name: Dost Öngür, MD, PhD
- Phone Number: 617-855-3922
- Email: dongur@partners.org
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Recruiting
- McLean Hospital
-
Contact:
- Julie M McCarthy, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria for Family Members:
- Ages 18-70.
Having a relative who:
- Is a client with early course psychosis (schizophrenia, schizoaffective disorder, schizophreniform, psychosis not otherwise specified (NOS), delusional disorder, brief psychotic disorder, major depression with psychosis, and bipolar disorder with psychosis (as reported by family member, clinician, or chart review)) with first onset in the past 6 years, and
- Used alcohol or cannabis in the past 30 days and/or has no apparent immediate interest in abstinence (responding "No" to "Do you think they want to quit right now?" in reference to overall substance use).
- Family member has concerns about the relative's substance use.
- The person(s) who can best describe the client with psychosis.
- At least 4 days per month contact with the client.
- Access to a computer with internet or mobile phone with video conferencing capabilities.
- Ability to provide written informed consent.
- Speak and read English.
Exclusion Criteria for Family Members:
- DSM-5 moderate or severe substance use disorder in the past year.
- Lifetime psychotic disorder.
- History of domestic violence with the client relative that would interfere with the ability to safely follow through with the intervention plan.
- Psychiatric, cognitive, or medical impairments that would interfere with the ability to follow through with the intervention plan.
- Prior participation of a family member of the client in the study program.
- Significant prior experience with CRAFT (e.g., having completed a CRAFT course prior to study enrollment)
Inclusion Criteria for Client Relatives:
- Ages 18-35.
- First episode psychosis onset in the past 6 years with a Diagnostic and Statistical Manual (DSM)-5 diagnosis of affective (bipolar disorder or major depressive disorder with psychotic features) or non- affective psychosis (schizophrenia spectrum disorder)
- Used alcohol or cannabis in the past 30 days and/or has no apparent immediate interest in abstinence (responding "No" to "Do you want to quit right now?" in reference to overall substance use).
- They or others have concerns about the client's substance use.
- Ability to provide written informed consent (or assent with their legal guardian providing informed consent)
- Speak and read English.
Exclusion Criteria for Client Relatives:
- N/A
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CRAFT-EP + TAU
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) with 8 weekly sessions of 60-90-minute coaching + Treatment as Usual (TAU).
|
CRAFT-EP is a behavioral intervention delivered via telehealth with the option for one in-person session (when local guidelines allow in-person care without masks).
The coaching session topics include self-care, communication, functional analysis, positive reinforcement, treatment engagement, natural consequences, problem solving, and planning next steps.
The intervention is designed for families of individuals experiencing psychosis and substance use who are enrolled or seeking enrollment in early psychosis outpatient services.
Participants will be asked to complete assessments at pre-, mid- (approximately week 4), post-intervention, and a follow-up assessment approximately 12 weeks post-intervention.
Other Names:
Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
Other Names:
|
Active Comparator: Treatment as Usual
|
Participants may continue to receive their ongoing treatment, if any, which may include psychosocial and/or pharmacological interventions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean readiness to change substance use
Time Frame: Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Mean readiness to cutdown/quit using [most problematic substance] for the client with psychosis using importance-confidence-readiness rulers (0 = not at all to 10 = extremely).
|
Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Session Attendance
Time Frame: Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Percentage of treatment sessions attended by the client with psychosis in past 30 days.
|
Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Substance Use
Time Frame: Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Client Timeline Follow Back (TLFB) past 30 day substance use, urine toxicology screen for drugs of abuse.
|
Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Family Wellbeing: Depression
Time Frame: Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Beck Depression Inventory-II total; scores range from 0 to 63 with higher scores representing more severe depressive symptoms.
|
Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Family Wellbeing: Anxiety
Time Frame: Baseline, mid-intervention (week 4), post-intervention (week 8)
|
State-Trait Anxiety Inventory-Short Form; total scores range from 6 to 24 with higher scores representing more severe anxiety symptoms.
|
Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Family Wellbeing: Relationship
Time Frame: Baseline, mid-intervention (week 4), post-intervention (week 8)
|
General Happiness item on Relationship Happiness Scale; scores range from 1 to 10 with higher scores representing greater relationship happiness.
|
Baseline, mid-intervention (week 4), post-intervention (week 8)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Julie M McCarthy, PhD, McLean Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 19, 2022
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
May 9, 2022
First Submitted That Met QC Criteria
May 13, 2022
First Posted (Actual)
May 19, 2022
Study Record Updates
Last Update Posted (Estimated)
November 8, 2023
Last Update Submitted That Met QC Criteria
November 6, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020P000220-A
- K23DA050808 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on CRAFT-EP
-
VA Office of Research and DevelopmentMinneapolis Veterans Affairs Medical Center; Corporal Michael J. Crescenz VA...RecruitingStress Disorders, Post-traumaticUnited States
-
Mclean HospitalNational Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Schizoaffective Disorder | Tobacco Use | Bipolar Disorder | Cannabis | Substance Use | Substance Use Disorders | Psychosis | Alcohol Use Disorder | Mental Disorder | Cigarette Smoking | Nicotine Use Disorder | Family | Marijuana | AlcoholUnited States
-
Stanford UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Southern... and other collaboratorsRecruitingAlcohol Drinking | Alcohol Use Disorder | Alcohol Abuse | Military Family | Relations, InterpersonalUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknownRefractory SchizophreniaBrazil
-
IrisZorgTerminatedSubstance Use Disorder | Addiction | Alcohol Use Disorder | Substance- Related DisorderNetherlands
-
University of New MexicoNational Institute on Drug Abuse (NIDA)CompletedSubstance Use Disorders | Family MembersUnited States
-
eXIthera PharmaceuticalsWithdrawnCovid19 | ThrombopeniaUnited States
-
Sunovion Respiratory Development Inc.Completed
-
University of CincinnatiNational Institute on Drug Abuse (NIDA); MaryhavenUnknownHeroin Dependence | Opiate Dependence | Substance DependenceUnited States
-
National Institute of Allergy and Infectious Diseases...Completed